Company:  EYEPOINT PHARMACEUTICALS, ... (EYPT)
Form Type:  DEF 14A
Filing Date:  4/28/2022 
CIK:  0001314102 
Address:  480 PLEASANT STREET
SUITE B300
 
City, State, Zip:  WATERTOWN, Massachusetts 02472 
Telephone:  617-926-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$10.59  
Change: 
-0.23 (-2.13%)  
Trade Time: 
03:48 PM EST  
Market Cap: 
$360.82M
Trade EYPT now with 

© 2022  
Description of Business
We are a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. Our pipeline leverages our proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration ("wet AMD"), the leading cause of vision loss among people 50 years of age and older in the United States. We also have two commercial products: YUTIQ®, a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, a single dose treatment for postoperative inflammation following ocular surgery. We are also advancing YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application ("sNDA") strategy.
Register and access this filing in:     
  FORM DEF 14A
    NOTICE OF 2022 ANNUAL MEETING OF STOCKHOLDERS
      NAME AND TITLE
      NAME AND TITLE
    Executive and Director Compensation Processes
    Audit Committee Report
      BENEFICIAL OWNERS
    EXECUTIVE OFFICER AND DIRECTOR COMPENSATION
      COMPENSATION TABLE
    PROPOSAL 1
    PROPOSAL 2
    PROPOSAL 3
    INFORMATION ABOUT STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS
    AVAILABILITY OF ANNUAL REPORT ON FORM 10-K